Security Snapshot

LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) Institutional Ownership

CUSIP: 528872302

13F Institutional Holders and Ownership History from Q2 2015 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

122

Shares (Excl. Options)

260,415,048

Price

$1.15

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
LXRX on Nasdaq
Shares outstanding
427,442,892
Price per share
$1.57
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
260,415,048
Total reported value
$299,475,172
% of total 13F portfolios
0%
Share change
+4,519,522
Value change
+$5,062,350
Number of holders
122
Price from insider filings
$1.57
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share is tracked under CUSIP 528872302.
  • 122 institutions reported positions in Q4 2025.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 122 to 9 between Q4 2025 and Q1 2026.
  • Reported value moved from $299,475,172 to $900,381.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 122 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 528872302?
CUSIP 528872302 identifies LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Invus Global Management, LLC 36% $177,944,476 154,734,327 Artal Participations S.a r.l. 29 Jan 2026
FMR LLC 10% +9% $26,696,274 +$2,516,037 38,137,535 +10% FMR LLC 30 Jun 2025

As of 31 Dec 2025, 122 institutional investors reported holding 260,415,048 shares of LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX). This represents 61% of the company’s total 427,442,892 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) together control 60% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Artal Group S.A. 32% 136,180,481 0% 22% $156,607,553
Siren, L.L.C. 9.1% 38,918,903 0% 1.3% $44,756,738
FMR LLC 8.9% 37,834,207 -2.2% 0% $43,509,338
VANGUARD GROUP INC 2.2% 9,606,549 +0.89% 0% $11,047,532
MILLENNIUM MANAGEMENT LLC 1.1% 4,821,733 +26% 0% $5,544,993
BlackRock, Inc. 0.75% 3,192,448 -6% 0% $3,671,316
UBS Group AG 0.7% 3,007,237 +752% 0% $3,458,322
Sessa Capital IM, L.P. 0.7% 3,000,000 0% 0.07% $3,450,000
GEODE CAPITAL MANAGEMENT, LLC 0.58% 2,500,022 +4.3% 0% $2,876,410
CIBC Private Wealth Group LLC 0.46% 1,950,000 -19% 0% $2,242,500
JANE STREET GROUP, LLC 0.4% 1,724,304 +278% 0% $1,982,950
CITADEL ADVISORS LLC 0.4% 1,710,975 -35% 0% $1,967,621
MARSHALL WACE, LLP 0.3% 1,262,367 0% $1,451,722
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.28% 1,207,242 +25% 0% $1,388,329
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.25% 1,055,123 -7.8% 0% $1,213,391
GSA CAPITAL PARTNERS LLP 0.23% 996,235 -17% 0.1% $1,146,000
GOLDMAN SACHS GROUP INC 0.22% 921,204 +1452% 0% $1,059,385
Hennion & Walsh Asset Management, Inc. 0.21% 901,222 +16% 0.04% $1,036,405
STATE STREET CORP 0.21% 884,738 +0.52% 0% $1,017,449
Ishara Investments LP 0.21% 880,000 0% 1.2% $1,012,000
ACADIAN ASSET MANAGEMENT LLC 0.15% 640,130 +1635% 0% $732,000
TWO SIGMA INVESTMENTS, LP 0.15% 637,308 +14% 0% $732,904
Invesco Ltd. 0.14% 594,883 +14% 0% $684,115
NORTHERN TRUST CORP 0.1% 412,164 +11% 0% $473,989
Compagnie Lombard Odier SCmA 0.1% 410,000 0% 0.01% $471,500

Institutional Holders of LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 587,378 $900,381 +$168,113 $1.57 9
2025 Q4 260,415,048 $299,475,172 +$5,062,350 $1.15 122
2025 Q3 255,139,258 $344,428,817 -$1,045,992 $1.35 121
2025 Q2 256,310,843 $242,983,204 -$6,845,383 $0.95 121
2025 Q1 265,818,368 $122,485,430 -$18,132,306 $0.46 124
2024 Q4 297,662,439 $220,126,714 -$8,084,075 $0.74 124
2024 Q3 288,616,985 $453,067,592 -$48,604,221 $1.57 134
2024 Q2 278,343,151 $467,625,172 +$175,856,984 $1.68 121
2024 Q1 171,815,966 $412,351,239 -$24,970,122 $2.40 114
2023 Q4 182,858,180 $279,771,925 -$6,759,847 $1.53 103
2023 Q3 188,793,708 $205,786,015 -$5,677,228 $1.09 109
2023 Q2 191,326,157 $438,152,499 +$104,558,326 $2.29 121
2023 Q1 145,600,839 $353,808,486 -$2,997,119 $2.43 102
2022 Q4 146,885,188 $280,547,551 -$3,977,447 $1.91 100
2022 Q3 148,905,062 $357,360,311 +$72,603,615 $2.40 98
2022 Q2 118,779,098 $220,940,693 -$2,430,736 $1.86 82
2022 Q1 120,193,264 $251,304,091 -$5,565,361 $2.09 100
2021 Q4 121,559,642 $478,894,149 -$1,466,109 $3.94 108
2021 Q3 121,205,281 $583,005,732 +$17,343,707 $4.81 96
2021 Q2 117,708,489 $540,207,653 +$2,119,118 $4.59 105
2021 Q1 121,214,904 $711,532,085 +$117,190 $5.87 103
2020 Q4 122,029,255 $417,334,864 +$65,690,726 $3.42 100
2020 Q3 104,248,250 $150,106,719 -$5,093,677 $1.44 83
2020 Q2 107,177,053 $213,813,923 +$4,797,305 $1.99 99
2020 Q1 104,815,254 $204,388,139 -$17,170,082 $1.95 107
2019 Q4 107,178,320 $444,778,336 +$20,431,577 $4.15 110
2019 Q3 102,423,092 $308,322,526 -$29,982,037 $3.01 95
2019 Q2 105,227,688 $661,832,362 +$7,044,227 $6.29 105
2019 Q1 104,271,703 $579,706,451 -$6,638,791 $5.56 112
2018 Q4 105,373,335 $699,630,313 -$17,077,199 $6.64 117
2018 Q3 107,498,975 $1,147,115,789 -$30,046,816 $10.67 114
2018 Q2 104,426,400 $1,253,163,056 -$371,540 $12.00 114
2018 Q1 109,754,416 $939,672,485 -$14,099,435 $8.57 118
2017 Q4 111,338,432 $1,100,040,141 -$44,224,810 $9.88 123
2017 Q3 110,485,325 $1,357,861,811 -$5,704,402 $12.29 130
2017 Q2 110,542,385 $1,818,248,643 +$18,151,870 $16.45 129
2017 Q1 109,854,396 $1,575,293,760 +$120,009,363 $14.34 130
2016 Q4 106,295,065 $1,470,204,819 -$2,532,260 $13.83 140
2016 Q3 106,140,794 $1,917,259,558 +$249,235 $18.07 138
2016 Q2 110,750,409 $1,589,249,524 +$1,094,261 $14.35 134
2016 Q1 110,808,225 $1,323,993,000 +$13,960,287 $11.95 126
2015 Q4 109,649,652 $1,459,682,001 +$54,951,710 $13.31 116
2015 Q3 105,860,530 $1,136,914,006 +$98,139,625 $10.74 99
2015 Q2 96,818,089 $779,385,263 +$779,385,260 $8.05 86